Skip to main content
. 2022 Apr 1;24:81. doi: 10.1186/s13075-022-02761-6

Table 3.

Response to alemtuzumab at 6 and 12 months

AAV (n = 12) BD (n = 11) Total (n = 23)
At 6 months in CR 4/12 (33.3%) 2/11 (18.2%) 6/23 (26.1%)
At 6 months in PR 5/12 (41.6%) 5/11 (45.5%) 10/23 (43.5%)
At 6 months CR or PR 9/12 (75%) 7/11 (63.6%) 16/23 (69.5%)
At 12 months in CR 5/12 (41.6%) 4/11 (36.4%) 9/23 (39.1%)
At 12 months in PR 0/12 (0%) 1/11 (9.1%) 1/23 (4.4%)
At 12 months CR or PR 5/12 (41.6%) 5/11 (45.5%) 10/23 (43.5%)

CR complete response, PR partial response, AAV ANCA-associated vasculitis, BD Behçet’s disease